GleamWall
中文EN

CDIO Cardio Diagnostics Holdings, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1870144 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.8%
TTM net income YoY1.0%
TTM EPS YoY21.0%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-42,649.8%
Net margin-42,721.9%
FCF margin-38,090.8%
EBITDA margin-42,499.9%

Returns

ROE-93.5%
ROA-87.2%
ROIC (approx.)-136.2%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets6.0%
Debt / equity0.00x
Current ratio17.44x
Interest coverage-564.93x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue11.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$14,825$34,890$17,065$950$901
R&D expense$641,212$227,966$145,182$40,448$31,468
SG&A expense$5.03M$6.92M$6.94M$4.40M$470,563
Operating income-$6.48M-$8.37M-$7.24M-$4.55M-$620,448
Interest expense$14,801$18,640$6.74M——
Pretax income-$6.50M-$8.38M-$8.38M-$4.66M-$620,448
Income tax———$0$0
Net income-$6.50M-$8.38M-$8.38M-$4.66M-$620,448
EBITDA-$6.42M-$8.35M-$7.22M-$4.53M-$604,448
EPS (basic)-3.71-9.35-0.66-1.51-0.53
EPS (diluted)-3.71-9.35-0.66-1.51-0.53
Weighted avg. shares (diluted)1.75M896,42412.69M3.09M1.16M
Balance sheet
Cash & equivalents$0$7.83M$1.28M$4.12M$512,767
Receivables$8,126$18,612$4,960$0$901
Current assets$5.92M$8.79M$2.77M$5.89M$803,507
PP&E, net$700,115$672,861$571,873$0—
Intangibles—$5,333$21,333$37,333$53,333
Total assets$7.77M$10.62M$4.46M$6.25M$1.10M
Current liabilities$604,839$631,695$841,142$1.95M$124,434
Total liabilities$793,061$1.06M$1.50M$1.95M$33,885
Shareholders' equity$6.97M$9.56M$2.96M$4.30M$1.07M
Shares outstanding1.83M1.53M20.54M9.51M1.23M
Cash flow statement
Operating cash flow-$5.73M-$4.99M-$5.67M-$5.09M-$585,291
Capital expenditure$187,317$214,765$575,663——
Free cash flow-$5.91M-$5.21M-$6.25M——
Investing cash flow-$419,310-$404,190-$794,291-$368,001-$364,029
Financing cash flow$3.43M$11.94M$3.63M$9.06M$1.23M
Depreciation & amortization$65,233$19,738$19,182$16,000$16,000
Stock-based compensation$110,235$2.59M$1.28M$0$60,000

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.